Rethinking Schizophrenia: Care Pathways | European Congress of Psychiatry
06.04.2025 @ 12:30 - 13:15
EBC is pleased to have an e-poster viewing “Rethinking Pathways: Innovative Approaches to Identify Individuals Experiencing First-Episode Psychosis and Connect Them to Care” at the upcoming European Congress of Psychiatry, set to take place on 5-8 April 2025 in Madrid (Spain). The e-poster EPP178 will be presented from 12:30 – 13:15 on 6 April 2025 in the e-poster area (station 13).
The e-poster will feature the second phase of the Rethinking schizophrenia project, co-created by the European Brain Council (EBC) and the European Psychiatric Association (EPA), and will aim to examine health gains and societal impacts resulting from optimal healthcare interventions in comparison with current care or inadequate treatment. Additionally, this projects convert data evidence to policy recommendations on how to improve the care pathways.
With a typical onset during late adolescence or early adulthood, schizophrenia requires lifelong treatment, combining pharmacological and non-pharmacological approaches. Early symptom recognition and timely interventions can greatly enhance functional recovery, however recent reports have identified significant gaps in access to timely assessment and shared decision-making, compounded by the unprecedented demand for mental healthcare among young people. Such high demands create challenges for health care services in delivering not only timely and evidence-based care but also safe and person-centred, as recommended by the World Health Organization. There is a need to improve prevention and care of young individuals with first episode psychosis (the onset of schizophrenia) to safely and effectively transition between various types of care tailored according to individual needs.
To address these issues, the Rethinking Schizophrenia project is conducting an analysis of patient care pathways across nine European countries (Belgium, Denmark, France, Germany, Hungary, Italy, Poland, Spain, and the UK). This project aims to put forward an in-depth patient care pathway analysis in order to define specific strategies to advance the prevention and treatment of schizophrenia. Findings will inform policy recommendations to enhance care pathways for young individuals experiencing first-episode psychosis.
Graduated from the Medical Faculty, Charles University Prague in 1990 (M.D.); in 2001 obtained his Ph.D. in Neurosciences., in 2015 was appointed a Professor of Psychiatry at the Charles University in Prague. Since 1991, prof. Mohr works at the National Institute of Mental Health, Czechia (formerly the Prague Psychiatric Center), currently as the Clinical Director. From 1995 to 1998, he was a visiting scientist at the Nathan Kline Institute for Psychiatric Research in Orangeburg, New York. Dr. Mohr is a Professor of Psychiatry at the 3rd Medical Faculty, Charles University, teaching pre-graduate medical students in psychiatry and postgraduate students in the PhD program of Neurosciences. Between 2006 and 2009 was a Faculty member of the Vienna School of Clinical Research. Member of the EPA since 2000, (since 2023 member of the EPA Board, current Chair of the Psychopharmacology Section, member of the Section Neurodevelopmental disorders across the lifespan); representative of the Czech Psychiatric Association at the Council of the NPAs EPA; since 2012 member of the European Network Adult ADHD; member of the European Group for Research in Schizophrenia (EGRIS); current Vice-President of the Czech Psychiatric Association (President 2019-2022), Board Member of the Czech Neuro-psychopharmacological Society (President 2009-2011). His main research interests are Clinical Psychiatry and Neurosciences; prof. Mohr has been a principal investigator of numerous research projects funded by the national and international research foundations.
Learn more about the EBC activities at the Congress:
